While patients with acute myeloid leukemia (AML) are routinely treated with chemotherapy and other cell-killing therapies, ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced FDA approval to initiate COMPASSION-37/AK104-311 trial, a global multicenter Phase III trial in gastric cancer ...

Innovation is accelerating through bispecifics and dual payload strategies | Emerging ADC development approaches such as ...

Merck’s Keytruda, the category-defining CPI, reported $29.5 billion in revenue in 2024, with NSCLC representing an estimated 30% of its total sales. Keytruda is expected to approach $35 billion by ...

Marianne D'Amico-Ferrari has spent 29 years teaching in Trumbull. Families know her as steady and kind. Students describe her ...

Chemotherapy-induced neurotoxicity spans cognitive dysfunction (“chemo brain”), seizures, neuropathies, and encephalopathy. Mechanisms involve disruption of neural networks, altered hippocampal ...

CALABASAS, Calif., Sept. 10, 2025 (GLOBE NEWSWIRE) -- NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) (“NeOnc” or the “Company”), a multi-Phase 2 clinical-stage biopharmaceutical company pioneering ...

(Barcelona, Spain September 7, 2025, 10:45 a.m. CEST / UTC +2) — Adding ivonescimab, a first-in-class bispecific antibody targeting both PD-1 and VEGF, to chemotherapy significantly prolonged ...

Hair is an important part of our personal identity, so its loss during cancer treatment can be distressing at an already difficult time. However, this can be a positive sign that chemotherapy is ...

Single-agent CD19 CAR-NK cell therapy achieved a complete response in third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkin lymphoma Second patient maintains an ongoing complete ...

Chemotherapy exposure created a pattern of mutations that was similar to normal aging, but the changes were premature and involved different genes. Chemotherapy can increase mutation burden and change ...